Ricardo Alvarez-Jimenez1,2, Ellen P Hart1, Samantha Prins1, Marieke de Kam1, Joop M A van Gerven1,3, Adam F Cohen1,4, Geert Jan Groeneveld1,5. 1. Centre for Human Drug Research, Zernikedreef 8, 2333, CL, Leiden, The Netherlands. 2. Anesthesiology Department, Vrije Universiteit Medisch Centrum (VU University Medical Center), De Boelelaan 1117, 1081, HV, Amsterdam, The Netherlands. 3. Neurology Department, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. 4. Internal Medicine Department, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. 5. Neurology Department, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, The Netherlands.
Abstract
AIMS: Establishing a pharmacological challenge model could yield an important tool to understand the complex role of the nicotinic cholinergic system in cognition and to develop novel compounds acting on the nicotinic acetylcholine receptor. METHODS: This randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study examined the effects of the nicotinic antagonist mecamylamine on a battery of cognitive and neurophysiological test with coadministration of a placebo, nicotine or galantamine in order to reverse the cognitive impairment caused by mecamylamine. RESULTS:Thirty-three healthy subjects received a single oral dose of 30 mg of mecamylamine (or placebo) in combination with either 16 mg of oral galantamine or 21 mg of transdermal nicotine (or its double-dummy). Mecamylamine 30 mg induced significant disturbances of cognitive functions. Attention and execution of visual (fine) motor tasks was decreased, short- and long-term memory was impaired and the reaction velocity during the test was slower when compared to placebo. Mecamylamine 30 mg produced a decrease in posterior α and β power in the surface electroencephalogram, effects that were reversed by nicotine coadministration. Memory and motor coordination tests could be partially reversed by the coadministration of nicotine. CONCLUSIONS:Mecamylamine administration induced slowing of the electroencephalogram and produced decrease in performance of tests evaluating motor coordination, sustained attention and short- and long-term memory. These effects could be partially reversed by the coadministration of nicotine, and to a lesser extent by galantamine.
RCT Entities:
AIMS: Establishing a pharmacological challenge model could yield an important tool to understand the complex role of the nicotinic cholinergic system in cognition and to develop novel compounds acting on the nicotinic acetylcholine receptor. METHODS: This randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study examined the effects of the nicotinic antagonist mecamylamine on a battery of cognitive and neurophysiological test with coadministration of a placebo, nicotine or galantamine in order to reverse the cognitive impairment caused by mecamylamine. RESULTS: Thirty-three healthy subjects received a single oral dose of 30 mg of mecamylamine (or placebo) in combination with either 16 mg of oral galantamine or 21 mg of transdermal nicotine (or its double-dummy). Mecamylamine 30 mg induced significant disturbances of cognitive functions. Attention and execution of visual (fine) motor tasks was decreased, short- and long-term memory was impaired and the reaction velocity during the test was slower when compared to placebo. Mecamylamine 30 mg produced a decrease in posterior α and β power in the surface electroencephalogram, effects that were reversed by nicotine coadministration. Memory and motor coordination tests could be partially reversed by the coadministration of nicotine. CONCLUSIONS:Mecamylamine administration induced slowing of the electroencephalogram and produced decrease in performance of tests evaluating motor coordination, sustained attention and short- and long-term memory. These effects could be partially reversed by the coadministration of nicotine, and to a lesser extent by galantamine.
Authors: J C Webster; M M Francis; J K Porter; G Robinson; C Stokes; B Horenstein; R L Papke Journal: Br J Pharmacol Date: 1999-07 Impact factor: 8.739
Authors: Lineke Zuurman; Paul C C M Passier; Marieke L de Kam; Huub J Kleijn; Adam F Cohen; Joop M A van Gerven Journal: J Psychopharmacol Date: 2009-11-25 Impact factor: 4.153
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Stephen Ph Alexander; John A Peters; Eamonn Kelly; Neil V Marrion; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld Journal: Br J Clin Pharmacol Date: 2018-02-20 Impact factor: 4.335
Authors: Charlotte Bakker; Tim Tasker; Jan Liptrot; Ellen P Hart; Erica S Klaassen; Robert Jan Doll; Giles A Brown; Alastair Brown; Miles Congreve; Malcolm Weir; Fiona H Marshall; David M Cross; Geert Jan Groeneveld; Pradeep J Nathan Journal: Alzheimers Res Ther Date: 2021-04-21 Impact factor: 6.982
Authors: Sofia Eickhoff; Leon Franzen; Alexandra Korda; Helena Rogg; Valerie-Noelle Trulley; Stefan Borgwardt; Mihai Avram Journal: Front Psychiatry Date: 2022-07-06 Impact factor: 5.435